Ligand Pharmaceuticals LGND Lease amortization expense
Lease amortization expense at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's lease amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's lease amortization expense?
- Ligand Pharmaceuticals (LGND) reported lease amortization expense of $479K in Q1 2026.
- How has Ligand Pharmaceuticals's lease amortization expense changed year-over-year?
- Ligand Pharmaceuticals's lease amortization expense decreased by 16.1% year-over-year, from $571K to $479K.
- What is the long-term trend for Ligand Pharmaceuticals's lease amortization expense?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's lease amortization expense has grown at a -29.4% compound annual growth rate (CAGR), from $5.52M to $1.94M.
- What does lease amortization expense mean?
- This represents the non-cash expense associated with the amortization of right-of-use assets recognized under lease accounting standards. It reflects the systematic allocation of the cost of leased assets over the lease term. Investors use this to normalize operating expenses by separating the non-cash depreciation of lease assets from actual cash lease payments.